Purpose Nipple-sparing mastectomy, which may improve cosmesis, body image, and sexual function in comparison to non-nipple-sparing mastectomy, is increasingly used to treat early-stage breast cancer; however, long-term survival data are lacking. We evaluated survival after nipple-sparing mastectomy versus non-nipple-sparing mastectomy in a population-based cancer registry. Methods We conducted an observational study using the California Cancer Registry, considering all stage 0-III breast cancers diagnosed in California from 1988 to 2013. We compared breast cancer-specific and overall survival time after nipple-sparing versus non-nipple-sparing mastectomy, using multivariable analysis. Results Among 157,592 stage 0-III female breast cancer patients treated with unilateral mastectomy from 1988-2013, 993 (0.6 %) were reported as having nipplesparing and 156,599 (99.4 %) non-nipple-sparing mastectomies; median follow-up was 7.9 years. The proportion of mastectomies that were nipple-sparing increased over time (1988, 0.2 %; 2013, 5.1 %) and with neighborhood socioeconomic status, and decreased with age and stage.
Introduction
Despite randomized clinical trials demonstrating equivalent survival after breast conserving therapy versus mastectomy [1] , use of mastectomy (specifically, contralateral prophylactic mastectomy) has risen recently [2] . This coincided with increased uptake of genetic testing for cancer risk assessment [3, 4] , and with reports that prophylactic mastectomy reduces breast cancer risk among women with an inherited BRCA1/2 mutation [5] . Given evidence that mastectomy rates are rising, interest has grown in less invasive procedures such as nipple-sparing mastectomy (NSM) [6] . Compared to non-nipple-sparing mastectomy (non-NSM), NSM may improve cosmesis, body image, and sexual function [7] . However, concerns remain about NSM's safety with regard to breast cancer recurrence and survival. Randomized clinical trials do not and with neighborhood SES, and decreased with age ( Table 1 ). The median follow-up was 7.9 years (interquartile range, 3.6-14.0 years) for all patients and for those who had non-NSM, compared to 1.9 years (interquartile range, 0.7-5.5 years) for patients who had NSM (Supplemental Table) .
In both minimally and fully adjusted models, NSM was associated with lower breast cancer-specific mortality than non-NSM (hazard ratio, HR 0.71, 95 % confidence interval, CI 0.51-0.98 fully adjusted, Table 2 ). In a secondary analysis limited to diagnoses in 1996 or later, a decreased risk with NSM was seen in the minimally adjusted model (HR 0.61, 95 % CI, 0.38-0.98), but the effect was attenuated in the fully adjusted model (HR 0.79, 95 % CI, 0.48-1.30, data not shown), and further attenuated after adjusting for grade, ER/PR status, and insurance (HR 0.86, 95 % CI, 0.52-1.42).
In both minimally and fully adjusted models, NSM was not associated with overall mortality (Table 2) . In a subset with diagnoses in 1996 or later, NSM was associated with lower overall mortality compared with non-NSM in a minimally adjusted model, but the effect was no longer significant after adjustment for all covariates.
Discussion
To the best of our knowledge, this is the largest populationbased study of mortality among breast cancer patients treated with NSM compared to non-NSM, with longer median follow-up (7.9 years) than previously reported. Consistent with prior studies [6, [9] [10] [11] [12] [13] [14] , we found no evidence of worse survival after NSM in this ''real world'' setting. In fact, NSM was associated with better survival than non-NSM; however, this association did not persist in Our study has limitations. Most notably, we had to restrict our assessment to patients having unilateral mastectomy, because SEER and other registries do not capture the nipple-sparing status of bilateral mastectomies. Given the benefits of prophylactic bilateral mastectomy for patients with hereditary breast cancer [5] and the growing interest in bilateral NSM as a less invasive approach for primary breast cancer prevention in high-risk women [13] , comparing outcomes of bilateral NSM versus bilateral non-NSM would be clinically valuable. This limitation should be addressed by adding detail about nipple-sparing status to routinely collected registry data items regarding bilateral mastectomy. Other gaps in registry data include family history and inherited genetic mutation status; however, we would not expect major differences in hereditary risk between the two groups that received unilateral mastectomy. Another potential concern is the possibly differential coding of NSM by hospital cancer registrars, which could result in misclassification of some NSM as non-NSM. There was differential follow-up time between patients who received non-NSM compared to NSM; however, the multivariable models that we used controlled for this difference. Moreover, results that included only the more recently diagnosed patients (1996-2013) were similar to those of the full cohort (1988-2013), which offers evidence that our findings are robust to differences in follow-up time. Despite these limitations, however, our study offers considerable strengths: it encompasses the full and diverse population of California, minimizes selection bias and provides results that can be generalized broadly. In the absence of randomized clinical trials, our comprehensive observational study of 157,592 breast cancer patients offers the best available evidence regarding the comparable survival between NSM and non-NSM.
Conclusion
Among California breast cancer patients diagnosed from 1988 to 2013, nipple-sparing mastectomy was not associated with worse survival than non-nipple-sparing mastectomy. These results may inform decisions of patients and doctors deliberating between these surgical approaches for breast cancer treatment. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
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